Edition:
United Kingdom

ALK-Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

918.00DKK
12 Dec 2018
Change (% chg)

-- (--)
Prev Close
kr.918.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,385
52-wk High
kr.1,230.00
52-wk Low
kr.646.00

Latest Key Developments (Source: Significant Developments)

ALK-Abello Q3 Total Revenue Falls To DKK 661 Million
Friday, 9 Nov 2018 

Nov 9 (Reuters) - ALK-Abello A/S ::REG-NINE-MONTH INTERIM REPORT (Q3) 2018.Q3 TOTAL REVENUE DKK 661 MILLION VERSUS DKK 667 MILLION YEAR AGO.FULL-YEAR OUTLOOK HAS SLIGHTLY IMPROVED COMPARED WITH Q2 REPORT, WHICH WAS RELEASED ON 15 AUGUST 2018..Q3 OPERATING PROFIT (EBITDA) WAS DKK 24 MILLION (36).FULL-YEAR REVENUE IS NOW PROJECTED TO BE DKK 2,850-2,900 MILLION (PREVIOUSLY: MORE THAN DKK 2.8 BILLION)..FY OPERATING PROFIT (EBITDA) IS NOW EXPECTED AT DKK 50-100 MILLION (PREVIOUSLY AROUND DKK 50).2018 FREE CASH FLOW IS NOW EXPECTED AT MINUS DKK 500 MILLION OR BETTER (PREVIOUSLY: MINUS DKK 550 MILLION OR BETTER).ALK WILL CONTINUE TO INVEST SIGNIFICANTLY IN STRATEGIC TRANSFORMATION OF COMPANY IN Q4.  Full Article

ALK: Torii Secures Pricing For New Japanese Cedar Slit-Tablet
Wednesday, 18 Apr 2018 

April 18 (Reuters) - ALK-ABELLO A/S ::ALK’S PARTNER FOR JAPAN, TORII, SECURES PRICING FOR NEW JAPANESE CEDAR SLIT-TABLET.TORII PHARMACEUTICAL SECURED A LISTING ON JAPAN’S NATIONAL HEALTH INSURANCE REIMBURSEMENT LIST FOR SLIT TABLET.LISTING CLEARS THE WAY FOR THE FORTHCOMING LAUNCH OF CEDARCURE, WHICH IS EXPECTED TO TAKE PLACE IN THE COMING MONTHS..ALK IS ENTITLED TO RECEIVE ROYALTIES OF SALES OF CEDARCURE.  Full Article

ALK Enters Allergy Diagnostic Partnership With Rellergen In China
Wednesday, 11 Apr 2018 

April 11 (Reuters) - ALK-ABELLO A/S ::ALK ANNOUNCES ALLERGY DIAGNOSTIC PARTNERSHIP WITH RELLERGEN IN CHINA.GAINS RIGHTS TO MARKET RELLERGEN'S BIO-IC TECHNOLOGY IN MORE THAN 190 HOSPITALS ACROSS CHINA.PARTNERSHIP ADVANCES ALK'S STRATEGY OF EXPANDING INTO RELEVANT ADJACENT BUSINESS AREAS.EXPANDING PARTNERSHIP INTO OTHER MARKETS IS CURRENTLY BEING DISCUSSED..PARTNERSHIP GRANTS ALK EXCLUSIVE PROMOTIONAL RIGHTS TO MARKET RELLERGEN'S BIO-IC.  Full Article

ALK-Abello Provides Pricing In New Share Issue
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Alk-Abello A/S ALKb.CO::PRESS RELEASE PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S.PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S.- ON 11 DECEMBER 2017 ALK WILL ISSUE A TOTAL OF 92,076 NEW AA SHARES AND 920,760 NEW B SHARES AT DKK 690 PER SHARE.OFFERING RESULTING IN GROSS PROCEEDS FOR ALK IN THE AMOUNT OF DKK 698,856,840.  Full Article

Alk-Abelló to issue shares in private placement
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - ALK-ABELLO A/S ::ALK-ABELLÓ A/S TO ISSUE UP TO 92,076 AA SHARES AND UP TO 920,760 B SHARES IN A PRIVATE PLACEMENT.  Full Article

ALK-Abello To Invest Around DKK 1 Bln In North America​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - ALK-ABELLO A/S ::‍WILL INVEST APPROXIMATELY DKK 1 BILLION TO SUCCEED IN NORTH AMERICA​.‍2018 REVENUE IS EXPECTED TO BE SLIGHTLY BELOW 2017​.‍AFTER 2018, ALK EXPECTS TO DELIVER ORGANIC REVENUE GROWTH OF 10% OR MORE ANNUALLY​.OVER NEXT FIVE YEARS, ANNUAL TOTAL RESEARCH AND DEVELOPMENT COSTS ARE EXPECTED TO BE IN RANGE OF DKK 400-600 MILLION.SAYS ‍NEW FINANCING IS EXPECTED TO COVER A PROJECTED ACCUMULATED NEGATIVE FREE CASH FLOW OF DKK 1 BILLION​.CONTINUES TO EXPECT FULL-YEAR REVENUE AT AROUND DKK 2.9 BILLION AND OPERATING PROFIT OF DKK 225-250 MILLION.‍OVER NEXT FIVE YEARS, ANNUAL TOTAL RESEARCH AND DEVELOPMENT COSTS ARE EXPECTED TO BE IN RANGE OF DKK 400-600 MILLION​.‍WILL POSITION ITSELF TO PENETRATE NON-AIT MARKET​.  Full Article

Alk-Abello Q3 EBITDA falls to DKK 36 million
Friday, 10 Nov 2017 

Nov 10 (Reuters) - ALK-ABELLO A/S :Q3 TOTAL REVENUE DKK ‍667​ MILLION VERSUS DKK 630 MILLION YEAR AGO.‍FINANCIAL GUIDANCE FOR FULL-YEAR REVENUE HAS BEEN NARROWED WHILE GUIDANCES FOR OPERATING PROFIT (EBITDA) AND FREE CASH FLOW REMAIN UNCHANGED​.‍FULL-YEAR REVENUE IS NOW PROJECTED AT APPROXIMATELY DKK 2.9 BILLION (PREVIOUSLY DKK 2.8-3.0 BILLION)​.Q3 ‍OPERATING PROFIT (EBITDA) WAS DKK 36 MILLION (110) FOLLOWING PLANNED COST INCREASES TO SUPPORT LONG-TERM GROWTH​.‍2017 OPERATING PROFIT (EBITDA) IS STILL EXPECTED TO BE DKK 225-250 MILLION.​.2017 ‍FREE CASH FLOW IS STILL EXPECTED AT APPROXIMATELY MINUS DKK 700 MILLION.​.REUTERS POLL: Q3 TOTAL REVENUES DKK 677 MILLION, GROUP EBIT LOSS DKK 22.5 MILLION ‍​.  Full Article

ALK-Abello says Jupiter Asset Management reduced ownership in ALK to below 5 pct of share capital​
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - ALK-Abello A/S - :‍Received notification from Jupiter Asset Management, that Jupiter reduced ownership in ALK to below 5% of share capital​.  Full Article

Alk-Abello acts on French injunction
Friday, 22 Sep 2017 

Sept 22 (Reuters) - ALK-ABELLO A/S :ALK-ABELLO A/S - FRENCH NATIONAL AGENCY FOR MEDICINES AND HEALTH PRODUCTS SAFETY ISSUED INJUNCTION AGAINST ALK.ALK-ABELLO A/S - INJUNCTION ISSUED AGAINST ALK LINKED TO NEEDED UPGRADES OF QUALITY SYSTEM AT ITS MANUFACTORING FACILITY IN VANDEUIL.ALK HAS TEMPORARILY STOPPED PRODUCTION IN STERILE AREA AND HALTED RELEASE OF ALL PRODUCTS MANUFACTURED THERE.ALK-ABELLO - ANSM INSTRUCTED CO TO MAKE QUALITY IMPROVEMENTS TO FACILITY, PREDOMINANTLY STRENGTHENING OF ENVIRONMENTAL MONITORING, DEVIATION HANDLING.ALK-ABELLO A/S - AS PRECAUTIONARY MEASURE, CO HAS INITIATED RECALL OF ALL INJECTABLE SCIT PRODUCTS RELEASED FROM AFFECTED AREA SINCE MARCH 2017.ALK-ABELLO A/S - TEMPORARY HALT IN PRODUCTION WILL LEAD TO SCIT PRODUCTS AND SKIN PRICK TESTS BEING IN SHORT SUPPLY UNTIL SITUATION IS FULLY REMEDIED.ALK EXPECTS ONLY A LIMITED, NEGATIVE SPILL-OVER EFFECT ON SALES OF OTHER PRODUCTS.EXPECTS THAT SUSPENSION WILL HAVE A SLIGHTLY NEGATIVE EFFECT ON ITS FULL-YEAR REVENUE.EXPECTS EXTRA COSTS ASSOCIATED WITH NEEDED UPGRADE OF QUALITY SYSTEM.2017 FULL-YEAR GUIDANCE REMAINS UNCHANGED.  Full Article